Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $1.90M | $7.60M | $1.00M | $0.00 | — | — |
| Revenue growth | — | — | — | — | — | 300.0% | -86.8% | -100.0% | — | — |
| Operating income | -$16.0M | -$23.0M | — | -$20.0M | -$17.0M | -$25.3M | -$42.0M | -$37.9M | -$31.5M | -$28.3M |
| Operating margin | — | — | — | — | -893.8% | -332.8% | -4195.0% | — | — | — |
| Net income | -$17.7M | -$23.8M | -$27.7M | -$19.3M | -$16.8M | -$20.7M | -$41.3M | -$37.3M | -$30.9M | -$26.9M |
| Net margin | — | — | — | — | -881.9% | -272.4% | -4130.1% | — | — | — |
| EPS (diluted) | -$18.66 | -$10.44 | -$157.72 | -$10.92 | -$2.11 | -$1.34 | -$2.13 | -$1.34 | -$0.50 | -$0.25 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.8M | -$11.0M | -$30.4M | -$17.6M | -$10.4M | -$26.0M | -$23.8M | -$31.4M | -$35.4M | -$28.4M |
| Capital expenditures | $6.00K | — | — | — | — | — | — | — | — | — |
| Free cash flow | -$11.9M | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | $0.00 | $487K | $0.00 | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.96M | $2.32M | $5.34M | $7.28M | $35.3M | $21.4M | $17.1M | $2.53M | $13.9M | $71.8M |
| Total assets | $6.42M | $33.5M | $16.9M | $16.6M | $46.0M | $26.3M | $20.9M | $6.22M | $19.4M | $78.3M |
| Total liabilities | $11.4M | $31.5M | $11.7M | $10.5M | $18.1M | $5.93M | $16.1M | $14.2M | $9.97M | $7.47M |
| Long-term debt | — | $2.61M | $0.00 | — | — | — | — | — | — | — |
| Shareholders' equity | -$5.00M | $2.07M | $5.25M | $6.09M | $28.0M | $20.3M | $4.85M | -$7.98M | $9.46M | $70.9M |
| Retained earnings | -$30.4M | -$54.2M | -$81.9M | -$101M | -$118M | -$139M | -$180M | -$217M | -$248M | -$275M |
| Shares (wtd avg diluted) | 1.27M | 5.77M | 441K | 5.08M | 7.98M | 15.5M | 19.4M | 27.8M | 61.2M | 109M |
Every figure is extracted from SELLAS Life Sciences Group, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.